HRSA orders Boehringer Ingelheim to comply with 340B drug pricing
The Health Resources andServices Administration (HRSA) has sent a letter to Boehringer Ingelheim ordering the pharmaceutical company to comply with federal requirements under the 340B drug pricing program. HRSA informed the company that its August 1 policy cutting off discounted pricing to hospitals on drugs dispensed at community-based pharmacies is unlawful. The agency
Source: healthcarefinancenews.com